(Total Views: 482)
Posted On: 12/15/2019 9:13:46 AM
Post# of 149715
Re: the lawman #12714
They will all fail. FDA will only approve, what can prove direct Cardiovescular Improvements. Just improving Biomarkers is a non event. Thats why Amarin spend 500Mio $ an did a 7 years study on Cardiovescular effects.
Despite that, only the EPA has the CV effects, and AMARN has patent protection on that till 2030.
I was trading MTNB twice in the last weeks, expecting a runup beacause of Amarin. But I did intensive DD, and there was no way I would hold it longer than for the hype.
Despite that, only the EPA has the CV effects, and AMARN has patent protection on that till 2030.
I was trading MTNB twice in the last weeks, expecting a runup beacause of Amarin. But I did intensive DD, and there was no way I would hold it longer than for the hype.
(2)
(0)Scroll down for more posts ▼
